In summary, this work adds to previous evidence linking potential therapeutic application of mGluR5 antagonists to obesity and obesity-related disorders, paving the way for the development of translational approaches and promised treatments. This evidence concerns the gene GRM5 and obesity due to melanocortin 4 receptor deficiency.